Shots:
- The Chinese NMPA has approved Boehringer Ingelheim‘s Jascayd for the treatment of adults with progressive pulmonary fibrosis (PPF)
- Approval was based on the P-III (FIBRONEER-ILD) trial of Jascayd vs PBO, which met its 1EP of reduced FVC at Wk. 52 & showed a significant reduction in death risk
- Additionally, Jascayd’ssNDA for PPF is under the US FDA’s review, plus submissions for both Idiopathic Pulmonary Fibrosis & PPF are under regulatory review in the EU, UK, Japan & other countries, with decisions anticipated in 2026
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim |Press Release
Related News: Boehringer Ingelheim and AimedBio Partner to Advance an ADC Therapeutic in Oncology
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
